

APPENDIX A—ESTABLISHED LIST OF THE CHEMICALS AND CHEMICAL COMPOUNDS IDENTIFIED BY FDA AS HARMFUL AND POTENTIALLY HARMFUL CONSTITUENTS IN TOBACCO PRODUCTS AND TOBACCO SMOKE—Continued

Constituent	Carcinogen (CA), respiratory toxicant (RT), cardiovascular toxicant (CT), reproductive or developmental toxicant (RDT), addictive (AD), poisonous chemical (PC), banned in food (in smokeless tobacco products)
N-Nitrosodiethanolamine (NDELA)	CA
N-Nitrosodiethylamine	CA
N-Nitrosodimethylamine (NDMA)	CA
N-Nitrosomethylethylamine	CA
N-Nitrosomorpholine (NMOR)	CA
N-Nitrosonorricotine (NNN)	CA
N-Nitrosopiperidine (NPIP)	CA
N-Nitrosopyrrolidine (NPYR)	CA
N-Nitrososarcosine (NSAR)	CA
Normicotine	AD
Phenol	RT, CT
PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine)	CA
Polonium-210	CA
Propionic Acid	RT
Propionaldehyde	RT, CT
Propylene Glycol	RT
Propylene oxide	CA, RT
Quinoline	CA
Selenium	RT
Styrene	CA
o-Toluidine	CA
Toluene	RT, RDT
Trp-P-1 (3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole)	CA
Trp-P-2 (1-Methyl-3-amino-5H-pyrido[4,3-b]indole)	CA
Uranium-235	CA, RT
Uranium-238	CA, RT
Vinyl acetate	CA, RT
Vinyl chloride	CA

Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
 [FR Doc. 2026-07910 Filed 4-22-26; 8:45 am]
BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Notice of Funding Extension for the Rural Communities Opioid Response Program—Behavioral Health Care Technical Assistance

AGENCY: Health Resources and Services Administration (HRSA), Department of Health and Human Services.

ACTION: Notice of funding extension.

SUMMARY: The Rural Communities Opioid Response Program—Behavioral Health Care Technical Assistance (RCORP-TA) strengthens, through technical assistance, rural organizations’ capacity to develop multi-sector consortia that can plan, implement, and sustain programs that improve access to and quality of behavioral health care services, including substance use disorder/opioid use disorder services. This funded extension extends RCORP-TA’s one cooperative agreement award recipient from cohort fiscal year 2022, HRSA-22-064, for a one-time 1-year period (September 1, 2026, through August 31, 2027). The current recipient, JBS International, Inc (U6BRH32364) was funded for a 4-year period of performance (September 1, 2022, through August 31, 2026).

FOR FURTHER INFORMATION CONTACT: Jillian Causey, Deputy Director, Rural Strategic Initiatives Division, Federal Office of Rural Health Policy, HRSA, at jcausey@hrsa.gov and (301) 443-1493.

SUPPLEMENTARY INFORMATION:

Intended Recipient(s) of the Award: 1 Rural Communities Opioid Response Program—Behavioral Health Care Technical Assistance award.

Amount of Non-Competitive Award: \$10,000,000.

Project Period: September 1, 2026, to August 31, 2027.

Assistance Listing Number: 93.912.

Award Instrument: Cooperative Agreement.

Authority: Section 711(b)(5) of the Social Security Act (42 U.S.C. 912(b)(5)).

TABLE 1—RECIPIENT(S) AND AWARD AMOUNT(S)

Grant No.	Award recipient name	City, state	Award amount
U6BRH32364	JBS International, Inc	North Bethesda, MD	\$10,000,000

Justification: This funding provides a one-time 1-year extension of funding to

Rural Communities Opioid Response Program—Behavioral Health Care

Technical Assistance award recipient with a budget period of September 1,

2026–August 31, 2027. This extension will allow JBS International, Inc. to build on past and ongoing technical assistance provided to HRSA grant-recipients, providing subject matter expertise to help improve access and quality of behavioral health care services, including substance use disorder and opioid use disorder in rural communities. Project activities that are within their currently approved scope of work and will be extended for one budget period include trainings/webinars, coordination of peer networking and coaching opportunities, site visits, learning collaboratives, and the annual in-person grantee meeting.

Margaret. M. Bush,
Deputy Administrator.

[FR Doc. 2026–07876 Filed 4–22–26; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Heart, Lung, and Blood Advisory Council.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Advisory Council.

Date: June 9, 2026.

Closed: 12:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Claude D. Pepper Building, 31 Center Drive, Bethesda, MD 20894.

Meeting Format: In-Person.

Contact Person: Charisee Lamar, Ph.D., M.P.H., R.R.T., Director, Division of Extramural Research Activities, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 206–Q, Bethesda, MD 20892, 301–827–5517, lamarc@mail.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the

name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at <https://security.nih.gov/visitors/Pages/visitor-campus-access.aspx> for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: <https://www.nhlbi.nih.gov/about/advisory-and-peer-review-committees/advisory-council>, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: April 21, 2026.

Denise M. Santeufemio,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–07912 Filed 4–22–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, Training and Career Development: Behavioral Neuroscience, May 13, 2026, 09:00 a.m. to May 14, 2026, 06:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on April 16, 2026, 91 FR 20473, Doc. No. 2026–07338.

This meeting is being amended to change the Panel Name from Training and Career Development: Behavioral Neuroscience to Training and Career Development Review. The meeting is closed to the public.

Dated: April 21, 2026.

Sterlyn H. Gibson,

Program Specialist, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–07978 Filed 4–22–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Therapeutics and Mammalian Models in Cancer.

Date: May 28, 2026.

Time: 1:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Maureen Shuh, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 480–4097, maureen.shuh@nih.gov.

Name of Committee: Cell Biology Integrated Review Group; Cellular Signaling and Regulatory Systems Study Section.

Date: June 2, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Jimok Kim, Ph.D., Scientific Review Officer, Center for Scientific Review, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 827–6918, jimok.kim@nih.gov.

Name of Committee: Integrative, Functional and Cognitive Neuroscience Integrated Review Group; Neuroscience of Basic Visual Processes Study Section.

Date: June 4, 2026.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Kirk Thompson, Ph.D., Scientific Review Officer, Center for